Bio-Rad Laboratories Inc. (BIO)
NYSE: BIO
· Real-Time Price · USD
227.06
-0.55 (-0.24%)
At close: May 30, 2025, 3:59 PM
226.93
-0.06%
After-hours: May 30, 2025, 05:16 PM EDT
Bio-Rad Laboratories Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics Revenue | 1.54B | 1.49B | 1.45B | 1.52B | 1.31B | 1.41B | 1.41B | 1.36B | 1.32B | 1.31B | 1.43B | 1.41B | 1.37B | 1.36B |
| Clinical Diagnostics Revenue Growth | +3.26% | +2.64% | -4.28% | +16.14% | -7.56% | +0.01% | +3.75% | +2.83% | +0.98% | -8.51% | +1.73% | +3.11% | +0.12% | n/a |
| Life Science Revenue | 1.03B | 1.18B | 1.35B | 1.4B | 1.23B | 885.9M | 861.7M | 785.2M | 730.7M | 695M | 728.3M | 710M | 688.4M | 694.7M |
| Life Science Revenue Growth | -12.75% | -12.53% | -3.83% | +13.72% | +39.05% | +2.81% | +9.74% | +7.46% | +5.14% | -4.57% | +2.58% | +3.14% | -0.91% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas Revenue | 169.3M | 166.6M | 155.4M | 156.6M | 136.6M | 137.3M | 138.3M | 140.2M | 128.3M | 128.5M | 150.9M |
| Americas Revenue Growth | +1.62% | +7.21% | -0.77% | +14.64% | -0.51% | -0.72% | -1.36% | +9.28% | -0.16% | -14.84% | n/a |
| Asia Pacific Revenue | 521.6M | 563M | 639.4M | 688.4M | 546.5M | 505M | 495.5M | 461.3M | 427.1M | 392.2M | 417.5M |
| Asia Pacific Revenue Growth | -7.35% | -11.95% | -7.12% | +25.97% | +8.22% | +1.92% | +7.41% | +8.01% | +8.90% | -6.06% | n/a |
| Europe Revenue | 834.1M | 819.8M | 851.9M | 946.9M | 857.7M | 770.3M | 792M | 758.5M | 742.2M | 763.7M | 901.7M |
| Europe Revenue Growth | +1.74% | -3.77% | -10.03% | +10.40% | +11.35% | -2.74% | +4.42% | +2.20% | -2.82% | -15.30% | n/a |
| United States Revenue | 1.04B | 1.12B | 1.16B | 1.13B | 1B | 899.1M | 863.6M | 800.2M | 770.6M | 735M | 704.9M |
| United States Revenue Growth | -7.17% | -2.91% | +2.20% | +12.52% | +11.76% | +4.11% | +7.92% | +3.84% | +4.84% | +4.27% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 208.8M | 204M | 200.44M | 196.12M | 210.48M | 205.9M | 201.2M | 207.82M | 225.55M | 212.23M | 211.05M | 208.73M | 197.59M | 224.15M | 216.15M | 213.43M | 225.85M | 219.15M | 198.16M | 189.26M | 193.69M | 214.16M | 201.62M | 201.26M | 207.58M | 212.54M | 201.2M | 210.43M | 209.13M | 204.21M | 196.77M | 213.03M | 194.94M | 220.02M | 201.45M | 205.54M | 189.72M | 193.15M | 187.44M | 192.84M | 188.56M |
| Selling, General, and Administrative Revenue Growth | +2.35% | +1.78% | +2.20% | -6.82% | +2.23% | +2.33% | -3.19% | -7.86% | +6.28% | +0.56% | +1.11% | +5.64% | -11.85% | +3.70% | +1.28% | -5.50% | +3.06% | +10.59% | +4.70% | -2.29% | -9.56% | +6.22% | +0.18% | -3.05% | -2.33% | +5.64% | -4.39% | +0.62% | +2.41% | +3.78% | -7.63% | +9.28% | -11.40% | +9.22% | -1.99% | +8.34% | -1.78% | +3.04% | -2.80% | +2.28% | n/a |
| Research and Development Revenue | 73.5M | 81.62M | 91M | 59.3M | 63.98M | 62.21M | 43.53M | 65.04M | 74.95M | 66.2M | 69.95M | 67.03M | 62.54M | 69.87M | 64.48M | 63.39M | 73.91M | 65.77M | 59.55M | 51.98M | 49.3M | 57.07M | 47.94M | 50.12M | 47.58M | 53.07M | 49.24M | 47.45M | 49.43M | 76.82M | 61.37M | 62.62M | 49.49M | 57.54M | 49.92M | 52.17M | 48.59M | 55.89M | 43.34M | 46.55M | 47.2M |
| Research and Development Revenue Growth | -9.95% | -10.30% | +53.44% | -7.30% | +2.83% | +42.90% | -33.07% | -13.22% | +13.22% | -5.36% | +4.35% | +7.18% | -10.49% | +8.36% | +1.72% | -14.23% | +12.39% | +10.44% | +14.55% | +5.44% | -13.61% | +19.03% | -4.35% | +5.35% | -10.36% | +7.78% | +3.78% | -4.00% | -35.66% | +25.17% | -2.00% | +26.54% | -14.00% | +15.26% | -4.31% | +7.38% | -13.06% | +28.96% | -6.90% | -1.39% | n/a |